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Brief Report R esult s
Clinical Findings and Laboratory Analysis
The pedigree of the Norwegian family with autosomal dominant erythrocytosis is shown in Figure 1A . The affected family members typically presented with symptoms of headache and dizziness that rapidly disappeared after initiation of phlebotomy. 12 No incidents of venous or arterial thrombosis had occurred in a family member younger than 70 years of age in this pedigree.
The affected family members had hemoglobin levels above 180 g per liter in men or 160 g per liter in women, with the exception of one male family member (WG05), whose hemoglobin level was in the upper normal range, at 167 g per liter.
One child (WG20) had a hemoglobin level of 190 g per liter shortly after birth; we do not have data obtained during infancy for the other members of the family. Additional laboratory data are provided in Table S1 in the Supplementary Appendix. Erythropoietin concentrations in serum were elevated in most of the affected family members. When plotted against the linear regression calculated from hemoglobin and serum erythropoietin levels of healthy persons, 13 the erythropoietin level was found to be elevated in relation to the hemoglobin level in each affected family member (Fig. 1B) .
Genomewide Linkage Analysis and DNA Sequencing
Sequence analysis of genes that are known to be involved in erythrocytosis yielded negative results. Therefore, we performed genomewide linkage analysis and found a cosegregating region on chromosome 7q22.1 with a LOD score of 3.3 ( (Table S2 in the Supplementary Appendix) revealed a heterozygous single-base deletion in exon 2 of EPO (chromosome 7: 100,319,199 GG→G) as the only candidate gene mutation (Fig. 1D) . This c.32delG mutation (referred to in this report as ΔG) was present in all affected family members (Fig. 1A) and was absent from 138,632 exome and wholegenome sequences reported in the Genome Aggregation Database (gnomAD).
14 Since erythropoietin is the primary regulator of erythropoiesis, the EPO ΔG deletion was an excellent candidate for the disease-causing mutation. The deletion creates a frameshift that truncates the erythropoietin signal peptide and generates a novel peptide, terminating after an additional 51 amino acids (Fig. 1E) , which would predict a loss of erythropoietin function and is at odds with the erythrocytosis phenotype.
Functional Characterization of the Mutated EPO
To determine whether alternative transcripts of EPO played a role in the phenotype of these patients, we used CRISPR to introduce the ΔG mutation into EPO. Since we had no access to kidney or liver tissues from the patients and were unable to detect EPO mRNA in erythroid colonies grown in vitro from a patient's peripheral blood, 15, 16 we introduced the mutation into EPO in Hep3B cells, a human hepatoma cell line that expresses EPO. 17 CRISPR-mediated genome editing ( We selected two Hep3B single-cell derived clones (ΔG 1 and ΔG 4 ) that were homozygous for the EPO ΔG mutation and assayed erythropoietin in the supernatants of these clonal cell lines grown in normoxic conditions; the supernatants contained 8 to 10 times as much erythropoietin as the supernatants of parental Hep3B cells or Hep3B cells in which CRISPR failed to modify EPO (Fig. 2B) . These supernatants were capable of stimulating the growth of an erythropoietindependent cell line (BaF3-EpoR), which suggested that the secreted erythropoietin was biologically active (Fig. 2C) . The same conclusions were reached with Hep3B cells grown in hypoxic conditions (Fig. S3 in the Supplementary Appendix). We therefore concluded that the ΔG deletion is, in fact, a gain-of-function mutation.
Study of EPO mRNA Transcripts
To understand how an ostensibly loss-of-function variant of EPO produces erythropoietin, we searched for alternative EPO mRNAs. In addition to the expected transcripts originating from the physiologic promoter (P1) upstream of exon 1, we discovered two alternative EPO mRNA transcripts that originate from an alternative promoter (P2) in intron 1 (Fig. 2D, and Fig. S4A in the Supplementary Appendix). The shorter transcript results from a splicing event that removes 189 nucleotides from the longer intron 1 tran-T h e ne w e ngl a nd jou r na l o f m e dicine script. We detected these two transcripts in parental Hep3B cells as well as in the ΔG clones; the longer P2 transcript was more abundant in the ΔG 1 and ΔG 4 clones than in parental Hep3B cells when grown in either normoxic (Fig. 2E) or hypoxic conditions. P1 and P2 transcripts were also detected in mRNA from normal kidney and liver (Fig. 2F) . In kidney, the P1 transcript was 
predominant, whereas in the liver, the long P2 mRNA was predominant. In Hep3B cells, the presence of the ΔG mutation did not alter the rate of transcription from the P1 and P2 promoters. However, the ΔG P2 mRNAs had a longer half-life than did the wild-type P2 mRNAs, which suggested that increased mRNA stability is responsible for the elevated levels of expression of P2 transcripts observed in Hep3B cells with the ΔG mutation (Fig. 2E ). Additional information on the characterization of the P1 and P2 transcripts is provided in Figure S4 in the Supplementary Appendix. To determine which transcripts are capable of producing erythropoietin, we transfected HEK293 cells with complementary DNAs (cDNAs) representing P1 or P2 transcripts with or without the ΔG mutation and measured erythropoietin in culture supernatants. Cells transfected with ΔG P2 transcripts produced more erythropoietin than cells transfected with wild-type P1 cDNA (Fig. S5A in the Supplementary Appendix). These supernatants also stimulated the growth of erythropoietindependent BaF3-EpoR cells (Fig. S5B in the Supplementary Appendix) and supported the growth of erythroid colonies from human peripheral blood (not shown), which showed that ΔG P2 transcripts produce biologically active erythropoietin.
Translation of EPO mRNA Variants
We performed in vitro transcription-translation experiments and examined the composition of the open reading frames (ORFs) in EPO mRNAs to determine why more erythropoietin was produced by the short ΔG P2 cDNA construct than by the long ΔG P2 construct in transfected HEK293 cells (Fig. S5 in the Supplementary Appendix). In vitro translation of the short ΔG P2 transcript produced more erythropoietin than did translation of the long ΔG P2 transcript or the wild-type P1 mRNA because the splicing event eliminates most of the upstream ORFs, which inhibit translation. Since AUG1* (the first start codon in the P2 transcripts; asterisks are used here to highlight start codons located in intron 1) is located within a sequence context that is predicted to be weak at initiating translation (Table S3 in the Supplementary Appendix), 18 ribosomes are likely to skip AUG1* and initiate translation from the next available start codon, which, in the short ΔG P2 transcript, is AUG2, located in exon 2. In vitro translation of the long ΔG P2 mRNA, most likely initiating from upstream AUG3* located in intron 1, produced a larger erythropoietin molecule that was approximately 25 kDa in size. The smaller observed protein product, which is approximately 21.6 kDa in size, is consistent with initiation of translation from AUG2. Removing upstream ORF1 by deleting the 5′ untranslated region (ΔUTR) increased the translational efficiency of the wildtype P1 mRNA, as reported previously.
19 HEK293 cells expressing the ΔG P1 cDNA produced low amounts of erythropoietin. A likely explanation is that ribosomes can skip the physiologic start codon (AUG1) in the ΔG P1 mRNA and initiate translation from AUG2, which connects with the erythropoietin coding sequence through the ΔG . Panel E shows the location of the ΔG mutation and the resulting frameshift in the EPO mRNA. The wild-type EPO coding sequence is shown in red, and the sequences encoding the signal peptide and the mature protein are marked. The ΔG mutation induces a frameshift in the EPO mRNA sequence that truncates the signal peptide and generates a novel peptide, terminating after additional 51 amino acids (gray box). UTR denotes untranslated region.
T h e ne w e ngl a nd jou r na l o f m e dicine frameshift. Thus, erythropoietin protein from all ΔG transcripts appears to be produced by initiating translation from AUG2. Additional information on erythropoietin production by the P1 and P2 transcripts is provided in Figure S5 in the Supplementary Appendix.
Initiation of translation from AUG2 produces an erythropoietin protein with a shortened signal peptide (22 instead of 27 amino acids) and a novel N-terminal, which nevertheless was predicted by computer-based algorithm (SignalP 4. 1 20 ) to be functional (Fig. S6 in the Supplementary Appendix). To test this prediction, we generated a cDNA construct representing EPO ΔG that starts directly with AUG2 and lacks any upstream AUGs. This construct (P2 ΔG ΔUTR) was most active in producing erythropoietin in vitro and in transfected HEK293 cells; it also showed bio- logic activity in the BaF3-EpoR proliferation assay ( Fig. S5A and S5B in the Supplementary Appendix), which indicated that the shortened signal peptide is indeed functional.
Second EPO Allele Associated with Erythrocytosis
A father and daughter with erythrocytosis and a single C nucleotide deletion (ΔC) of unknown significance, which was located in EPO exon 2 just 13 nucleotides upstream of ΔG (c.19delC; chromosome 7: 100,319,185 TC→T), were recently described. 11 To test whether EPO ΔC has the same effect as EPO ΔG, we generated ΔC P2 cDNA constructs, transfected HEK293 cells, and measured erythropoietin protein and erythropoietin bioactivity in cell-culture supernatants. The long P2 and short P2 transcripts with the ΔC mutation also produced high amounts of erythropoietin that was biologically active (Fig. S7 in the Supplementary Appendix), which showed that the EPO ΔC mutation causes erythrocytosis through the same mechanism (Fig. 3) as the EPO ΔG mutation.
Discussion
We propose that the frameshift mutation ΔG in EPO causes erythrocytosis on the basis of genetic linkage with a locus on chromosome 7q21 (LOD score, 3.3), functional data, and our finding of a second, independent allele (ΔC) in a father and daughter with erythrocytosis. Both ΔG and ΔC cause a frameshift and convert a noncoding mRNA transcribed from an alternative (P2) promoter inside EPO intron 1 into an mRNA that produces functional erythropoietin protein. This frameshift occurs in the sequence encoding the signal peptide of erythropoietin; the mutant peptide sequence is fully functional. We dissected the relative contribution of individual upstream AUG start codons located in the 5′ untranslated regions of P1 and P2 transcripts and established that erythropoietin protein from both P2 ΔG transcripts appears to be produced by initiating translation from AUG2, located in exon 2.
P2 transcripts were more abundant in normal liver than in kidney, which suggested that the main source of erythropoietin production in affected family members was the liver. Indeed, P2 transcripts are present in human liver RNAseq data sets from ProteinAtlas 21 and the Illumina Human Body Map (Fig. S8 in the Supplementary Appendix). In a database of capped 5′ ends of mRNAs, 22, 23 P2 transcripts were the predominant mRNA species in the liver, whereas P1 transcripts were mainly detected in RNA from kidney (Fig.  S9 in the Supplementary Appendix) . The physiological function of wild-type P2 transcripts is currently unknown, but it seems likely that they do have a function, because EPO intron 1 has a high degree of sequence homology between human and mouse and the region of homologous sequence extends upstream of the P2 promotor (Fig. S10 in the Supplementary Appendix). 24 Our data indicate that the EPO ΔG mutation prematurely terminates translation of EPO P1 transcripts, whereas it alters the normally noncoding P2 transcripts such that AUG2 initiates translation of the erythropoietin coding sequence and produces an excess of biologically active erythropoietin. Mutations in EPO should be considered in the search for causes of inherited erythrocytosis. More generally, the effect of mutations on multiple mRNA transcripts may explain nonintuitive relationships between phenotype and the ostensible mechanism predicted by the mutation.
